NYSE - Nasdaq Real Time Price USD

Taro Pharmaceutical Industries Ltd. (TARO)

42.30 +0.10 (+0.24%)
At close: May 17 at 4:00 PM EDT
42.30 -0.07 (-0.15%)
After hours: May 17 at 4:02 PM EDT
Loading Chart for TARO
DELL
  • Previous Close 42.20
  • Open 42.35
  • Bid 42.14 x 1000
  • Ask 42.41 x 800
  • Day's Range 42.14 - 42.37
  • 52 Week Range 28.10 - 45.76
  • Volume 17,613
  • Avg. Volume 39,403
  • Market Cap (intraday) 1.59B
  • Beta (5Y Monthly) 0.60
  • PE Ratio (TTM) 34.67
  • EPS (TTM) 1.22
  • Earnings Date May 20, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date Dec 10, 2018
  • 1y Target Est 43.00

Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products. It offers its products for various therapeutic categories comprising allergy, analgesic, antibacterial, antibiotic, anticonvulsant, antiemetic, antifungal, anti-inflammatory, anti-cancer, antiplatelet agent, antipyretic, cardiovascular, CNS, corticosteroid, cosmetic, cough and cold, dermatology, diuretic, endocrine, gastrointestinal, laxative, narcotics, neuropathic pain, neuropsychiatric, sedative/hypnotic, and topical anti-neoplastic. The company provides its products in the form of capsule, cream, drops, emulsion, gel/gel kit, granules, injectable, lotion, oil, ointment, paste, powder/powder for solution, rectal suppository, shampoo, solution/solution for infusion, spray, suspension, syrup, tablets, toothpaste and mouthwash, topical foam, and topical solution. It distributes and sells its products directly to wholesalers, retail drug chains, food chains, hospitals, mass merchandisers, e-commerce stores, and other direct consumers, as well as healthcare institutions and private pharmacies. The company was incorporated in 1959 and is based in Haifa, Israel. Taro Pharmaceutical Industries Ltd. operates as a subsidiary of Alkaloida Chemical Company Zrt. As of June 30, 2023, Taro Pharmaceutical Industries Ltd. operates as a subsidiary of Sun Pharmaceutical Industries Limited.

www.taro.com

1,554

Full Time Employees

March 31

Fiscal Year Ends

Recent News: TARO

Performance Overview: TARO

Trailing total returns as of 5/17/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

TARO
1.24%
S&P 500
11.18%

1-Year Return

TARO
46.77%
S&P 500
29.04%

3-Year Return

TARO
42.80%
S&P 500
27.06%

5-Year Return

TARO
58.26%
S&P 500
84.38%

Compare To: TARO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: TARO

Valuation Measures

Annual
As of 5/17/2024
  • Market Cap

    1.59B

  • Enterprise Value

    741.49M

  • Trailing P/E

    34.67

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    2.60

  • Price/Book (mrq)

    0.89

  • Enterprise Value/Revenue

    1.21

  • Enterprise Value/EBITDA

    9.58

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    7.48%

  • Return on Assets (ttm)

    1.03%

  • Return on Equity (ttm)

    2.61%

  • Revenue (ttm)

    610.83M

  • Net Income Avi to Common (ttm)

    45.7M

  • Diluted EPS (ttm)

    1.22

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    902.22M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    81.01M

Research Analysis: TARO

Company Insights: TARO

Research Reports: TARO

People Also Watch